Aranesp news from FiercePharma
NewsNew drug-spending leader: Diabetes
New data on pharma sales details some big shifts in spending. Diabetes meds have displaced cholesterol drugs as the Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
Grassley: Amgen doc rebates skyrocket
Another day, another Grassley letter. You'll recall that earlier this week, Sen. Chuck Grassley demanded documents from Amgen relating to the company's promotions of its anemia drugs. Now, Grassley Read more...
Congress probes Amgen, J&J promos
Did Amgen and Johnson & Johnson over-promote their anemia drugs? Congress is asking the companies for documents detailing their advertising and promotions, including a "bundling" discount Amgen Read more...
Amgen: Mircera deal would set precedent
Should he or shouldn't he? The judge weighing the case of Amgen v. Roche is getting a lot of unsolicited advice on whether to allow Roche's anemia med Mircera onto the market. Last year, a jury ruled Read more...
FDA panel votes to restrict anemia drugs
Look on the bright side: It could have been worse. An FDA advisory panel voted to keep Amgen and Johnson & Johnson's anemia remedies on the market for cancer patients. So the drugs appear to have Read more...
FDA's worst-case anemia scenario
Here's a peek into the FDA playbook for tomorrow's advisory panel on Amgen and Johnson & Johnson's anemia drugs. According to documents posted on the agency website, those expert advisors will be Read more...
Do anemia warnings signal new limits?
Is it a pre-emptive strike? Late Friday Amgen added new warnings to the embattled anemia drugs Aranesp (Amgen) and Procrit (Johnson & Johnson). The labeling for those drugs now warns that they Read more...
Judge blocks Roche's Mircera--for now
Victory for Amgen--and maybe for Roche, too. The California drug maker persuaded a judge to temporarily ban Roche's competing anemia drug Mircera in the U.S. But the judge also said he'd consider Read more...
| Press ReleasesPRESS RELEASE: Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN - News) today announced that it had received Read more... PRESS RELEASE: Phase 2 Study Suggests That Extended Dosing of Aranesp is as Efficacious as Weekly Dosing Phase 2 Study Suggests That Extended Dosing of Aranesp is as Efficacious as Weekly Dosing Aranesp Combined Patient Level Analyses Provide Additional Evidence of Efficacy and Safety BARCELONA, Spain Read more... |
Get more Aranesp coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight